To the Editor: In a study of birth defects among the offspring of survivors of cancer in childhood and adolescence, Green et al. (July 18 issue) found congenital heart disease in 2 of 20 children born to eight women who received dactinomycin as part of their anticancer therapy.1 To see whether we could replicate this unexpected finding, we determined the occurrence of birth defects among the offspring of similar survivors studied at five centers by the National Cancer Institute.2 , 3 None of the 52 offspring born to 36 survivors ( 11 men and 25 women) who had been treated with dactinomycin. . .
ASJC Scopus subject areas